# Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

> **NCT00066196** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 110 (—)

## Conditions studied

- Melanoma
- Malignant Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** MEDI--522
- **BIOLOGICAL:** Integrin + Dacarbazine

## Key facts

- **NCT ID:** NCT00066196
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-04
- **Final completion:** 2007-06
- **Target enrollment:** 110 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066196, "Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00066196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*